Visitors Now:
Total Visits:
Total Stories:
Profile image
Story Views

Now:
Last Hour:
Last 24 Hours:
Total:

Wet (Neovascular / Exudative) Macular Degeneration Therapeutic Pipeline Market Review, H2 2016

Thursday, September 22, 2016 3:39
% of readers think this story is Fact. Add your two cents.

(Before It's News)

Wet (Neovascular / Exudative) Macular Degeneration Therapeutic Market 2016

Complete Report Details @ https://www.wiseguyreports.com/reports/649773-wet-neovascular-exudative-macular-degeneration-pipeline-review-h2-2016

The, ‘Wet (Neovascular / Exudative) Macular Degeneration – Pipeline Review, H2 2016’, provides an overview of the Wet (Neovascular / Exudative) Macular Degeneration pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Wet (Neovascular / Exudative) Macular Degeneration, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Wet (Neovascular / Exudative) Macular Degeneration and features dormant and discontinued projects.

For more information or any query mail at sales@wiseguyreports.com

The report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Get a Sample Report @ https://www.wiseguyreports.com/sample-request/649773-wet-neovascular-exudative-macular-degeneration-pipeline-review-h2-2016

Scope

- The report provides a snapshot of the global therapeutic landscape of Wet (Neovascular / Exudative) Macular Degeneration 
- The report reviews pipeline therapeutics for Wet (Neovascular / Exudative) Macular Degeneration by companies and universities/research institutes based on information derived from company and industry-specific sources 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved Wet (Neovascular / Exudative) Macular Degeneration therapeutics and enlists all their major and minor projects 
- The report assesses Wet (Neovascular / Exudative) Macular Degeneration therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type 
- The report summarizes all the dormant and discontinued pipeline projects 
- The report reviews latest news related to pipeline therapeutics for Wet (Neovascular / Exudative) Macular Degeneration

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies 
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Identify and understand important and diverse types of therapeutics under development for Wet (Neovascular / Exudative) Macular Degeneration 
- Identify potential new clients or partners in the target demographic 
- Develop strategic initiatives by understanding the focus areas of leading companies 
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics 
- Devise corrective measures for pipeline projects by understanding Wet (Neovascular / Exudative) Macular Degeneration pipeline depth and focus of Indication therapeutics 
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope 
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table Of Contents – Major Key Points

#Companies Involved in Therapeutics Development:

Aciont Inc. 25 
Adverum Biotechnologies, Inc. 26 
Allergan Plc 27 
Alteogen Inc. 28 
Amakem NV 29 
Ampio Pharmaceuticals, Inc. 30 
Apellis Pharmaceuticals, Inc. 31 
Apexigen, Inc. 32 
Applied Genetic Technologies Corporation 33 
Benitec Biopharma Limited 34 
Boehringer Ingelheim GmbH 35 
Cell Medica Limited 36 
Charlesson LLC. 37 
Cipla Ltd. 38 
Clanotech AB 39 
Clearside BioMedical, Inc. 40 
Clonz Biotech Private Limited 41 
Coherus BioSciences, Inc. 42 
Daiichi Sankyo Company, Limited 43 
Diffusion Pharmaceuticals Inc. 44 
Eleven Biotherapeutics Inc. 45 
Exonate Limited 46 
F. Hoffmann-La Roche Ltd. 47 
Formycon AG 48 
Graybug Vision Inc 49 
GTx, Inc. 50 
iCo Therapeutics Inc. 51 
Icon Bioscience, Inc. 52 
Iconic Therapeutics, Inc. 53 
Kala Pharmaceuticals, Inc. 54 
Kodiak Sciences Inc. 55 
Mabion SA 56 
MeiraGTx Limited 57 
Mitotech S.A. 58 
Ocular Therapeutix, Inc. 59 
Ohr Pharmaceutical Inc. 60 
Ophthotech Corp. 61 
Oxford BioMedica Plc 62 
PanOptica, Inc. 63 
Pfenex Inc. 64 
Pfizer Inc. 65 
pSivida Corp. 66 
Regeneron Pharmaceuticals Inc 67 
RegenxBio Inc. 68 
RXi Pharmaceuticals Corporation 69 
Santen Pharmaceutical Co., Ltd. 70 
Sanwa Kagaku Kenkyusho Co., Ltd. 71 
TRACON Pharmaceuticals, Inc. 72 
TWi Pharmaceuticals, Inc. 73 
Tyrogenex, Inc. 74 
Xbrane Biopharma AB 75 

Wet (Neovascular / Exudative) Macular Degeneration – Therapeutics Assessment 76 
Assessment by Monotherapy Products 76 
Assessment by Combination Products 77 
Assessment by Target 78 
Assessment by Mechanism of Action 81 
Assessment by Route of Administration 85 
Assessment by Molecule Type 87 
Drug Profiles 89 

…….CONTUNUED

For more information or any query mail at sales@wiseguyreports.com

Get Exclusive Discount On This Report @ https://www.wiseguyreports.com/check-discount/649773-wet-neovascular-exudative-macular-degeneration-pipeline-review-h2-2016

CONTACT US:

NORAH TRENT

Partner Relations & Marketing Manager

sales@wiseguyreports.com

www.wiseguyreports.com

Ph: +1-646-845-9349 (US)

Ph: +44 208 133 9349 (UK)

ABOUT US:

Wise Guy Reports is part of the Wise Guy Consultants Pvt. Ltd. and offers premium progressive statistical surveying, market research reports, analysis & forecast data for industries and governments around the globe. Wise Guy Reports features an exhaustive list of market research reports from hundreds of publishers worldwide. We boast a database spanning virtually every market category and an even more comprehensive collection of market research reports under these categories and sub-categories.

Report abuse

Comments

Your Comments
Question   Razz  Sad   Evil  Exclaim  Smile  Redface  Biggrin  Surprised  Eek   Confused   Cool  LOL   Mad   Twisted  Rolleyes   Wink  Idea  Arrow  Neutral  Cry   Mr. Green

Top Stories
Recent Stories

Register

Newsletter

Email this story
Email this story

If you really want to ban this commenter, please write down the reason:

If you really want to disable all recommended stories, click on OK button. After that, you will be redirect to your options page.